1. P20 Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: results of a secondary analysis from the month-18 interim analysis of the REGENERATE study. (28th September 2020) Authors: Digpal, Kuldip; Anstee, Quentin Journal: Gut Issue: Volume 69(2020)Supplement 1 Page Start: A16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P21 Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric MRI: interim results of the REGENERATE trial. (28th September 2020) Authors: Anstee, Quentin; Digpal, Kuldip Journal: Gut Issue: Volume 69(2020)Supplement 1 Page Start: A17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P22 Obeticholic acid improves transaminases in patients with non-alcoholic steatohepatitis: results from the 18-month interim analysis of the REGENERATE study. (28th September 2020) Authors: Allison, Michael; Sheridan, David; Digpal, Kuldip Journal: Gut Issue: Volume 69(2020)Supplement 1 Page Start: A18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P23 Predicted risk of end-stage liver disease utilizing the UK-PBC risk score with continued standard of care and subsequent addition of OCA for 60 months in patients with PBC. (28th September 2020) Authors: Mells, George; Jones, Dave; Digpal, Kuldip Journal: Gut Issue: Volume 69(2020)Supplement 1 Page Start: A18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗